Genmab Reports Strong Phase Ib/II Results for Epcoritamab Combo in r/r DLBCL

Genmab has announced encouraging results from Arm 10 of its Phase Ib/II EPCORE NHL-2 trial, evaluating epcoritamab plus R-ICE in relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) patients eligible for stem cell transplant.

The combo showed an 87% overall response rate (ORR), including 65% complete responses and 23% partial responses. At six months, 81% of responses were ongoing, 74% of patients remained progression-free, and all were alive.

Among those who relapsed within 12 months of first-line therapy, ORR was 85% and CR 55%; for those relapsing later, ORR reached 91% and CR 82%.

The safety profile was favorable, with only low-grade cytokine release syndrome and no treatment-related discontinuations.

Epcoritamab, developed with Genmab’s DuoBody technology, is a subcutaneously administered IgG1-bispecific antibody targeting B-cell non-Hodgkin’s lymphoma.

23-06-2025